Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Public ClinicalTrials.gov record NCT00931385. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil Iin Patients With Chronic Obstructive Pulmonary Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. Each patient will receive all four treatments.
Study identification
- NCT ID
- NCT00931385
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 99 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2009 (Type not available)
- Primary completion
- Apr 2010 (Actual)
- Completion
- Not listed
- Last update posted
- Jul 1, 2014
Started 2009
United States locations
- U.S. sites
- 11
- U.S. states
- 6
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1222.24.24011 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 1222.24.24009 Boehringer Ingelheim Investigational Site | Overland Park | Kansas | — | — |
| 1222.24.24007 Boehringer Ingelheim Investigational Site | Lafayette | Louisiana | — | — |
| 1222.24.24002 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1222.24.24010 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 1222.24.24004 Boehringer Ingelheim Investigational Site | Easley | South Carolina | — | — |
| 1222.24.24006 Boehringer Ingelheim Investigational Site | Gaffney | South Carolina | — | — |
| 1222.24.24005 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1222.24.24008 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1222.24.24001 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1222.24.24003 Boehringer Ingelheim Investigational Site | Union | South Carolina | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00931385, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 1, 2014 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00931385 live on ClinicalTrials.gov.